225 related articles for article (PubMed ID: 16389547)
21. Cannabidiol as a Potential Treatment for Anxiety Disorders.
Blessing EM; Steenkamp MM; Manzanares J; Marmar CR
Neurotherapeutics; 2015 Oct; 12(4):825-36. PubMed ID: 26341731
[TBL] [Abstract][Full Text] [Related]
22. Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells.
Libro R; Diomede F; Scionti D; Piattelli A; Grassi G; Pollastro F; Bramanti P; Mazzon E; Trubiani O
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025562
[TBL] [Abstract][Full Text] [Related]
23. Molecular Targets of Cannabidiol in Neurological Disorders.
Ibeas Bih C; Chen T; Nunn AV; Bazelot M; Dallas M; Whalley BJ
Neurotherapeutics; 2015 Oct; 12(4):699-730. PubMed ID: 26264914
[TBL] [Abstract][Full Text] [Related]
24. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
Crippa JA; Derenusson GN; Ferrari TB; Wichert-Ana L; Duran FL; Martin-Santos R; Simões MV; Bhattacharyya S; Fusar-Poli P; Atakan Z; Santos Filho A; Freitas-Ferrari MC; McGuire PK; Zuardi AW; Busatto GF; Hallak JE
J Psychopharmacol; 2011 Jan; 25(1):121-30. PubMed ID: 20829306
[TBL] [Abstract][Full Text] [Related]
25.
Watt G; Karl T
Front Pharmacol; 2017; 8():20. PubMed ID: 28217094
[TBL] [Abstract][Full Text] [Related]
26. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement.
Esposito G; Scuderi C; Valenza M; Togna GI; Latina V; De Filippis D; Cipriano M; Carratù MR; Iuvone T; Steardo L
PLoS One; 2011; 6(12):e28668. PubMed ID: 22163051
[TBL] [Abstract][Full Text] [Related]
27. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Zuardi AW; Crippa JA; Hallak JE; Bhattacharyya S; Atakan Z; Martin-Santos R; McGuire PK; Guimarães FS
Curr Pharm Des; 2012; 18(32):5131-40. PubMed ID: 22716160
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.
Weiss L; Zeira M; Reich S; Har-Noy M; Mechoulam R; Slavin S; Gallily R
Autoimmunity; 2006 Mar; 39(2):143-51. PubMed ID: 16698671
[TBL] [Abstract][Full Text] [Related]
29. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.
Martín-Moreno AM; Reigada D; Ramírez BG; Mechoulam R; Innamorato N; Cuadrado A; de Ceballos ML
Mol Pharmacol; 2011 Jun; 79(6):964-73. PubMed ID: 21350020
[TBL] [Abstract][Full Text] [Related]
30. Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC; Fogaça MV; Sonego AB; Guimarães FS
Pharmacol Res; 2016 Oct; 112():119-127. PubMed ID: 26845349
[TBL] [Abstract][Full Text] [Related]
31. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.
Linge R; Jiménez-Sánchez L; Campa L; Pilar-Cuéllar F; Vidal R; Pazos A; Adell A; Díaz Á
Neuropharmacology; 2016 Apr; 103():16-26. PubMed ID: 26711860
[TBL] [Abstract][Full Text] [Related]
32. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
Zuardi AW
Braz J Psychiatry; 2008 Sep; 30(3):271-80. PubMed ID: 18833429
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J
Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181
[TBL] [Abstract][Full Text] [Related]
34. Cannabidiol: a promising drug for neurodegenerative disorders?
Iuvone T; Esposito G; De Filippis D; Scuderi C; Steardo L
CNS Neurosci Ther; 2009; 15(1):65-75. PubMed ID: 19228180
[TBL] [Abstract][Full Text] [Related]
35. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.
Chagas MH; Zuardi AW; Tumas V; Pena-Pereira MA; Sobreira ET; Bergamaschi MM; dos Santos AC; Teixeira AL; Hallak JE; Crippa JA
J Psychopharmacol; 2014 Nov; 28(11):1088-98. PubMed ID: 25237116
[TBL] [Abstract][Full Text] [Related]
36. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression.
Esposito G; Scuderi C; Savani C; Steardo L; De Filippis D; Cottone P; Iuvone T; Cuomo V; Steardo L
Br J Pharmacol; 2007 Aug; 151(8):1272-9. PubMed ID: 17592514
[TBL] [Abstract][Full Text] [Related]
37. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors.
Castillo A; Tolón MR; Fernández-Ruiz J; Romero J; Martinez-Orgado J
Neurobiol Dis; 2010 Feb; 37(2):434-40. PubMed ID: 19900555
[TBL] [Abstract][Full Text] [Related]
38. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.
Booz GW
Free Radic Biol Med; 2011 Sep; 51(5):1054-61. PubMed ID: 21238581
[TBL] [Abstract][Full Text] [Related]
39. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.
Hampson AJ; Grimaldi M; Axelrod J; Wink D
Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8268-73. PubMed ID: 9653176
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease.
Karl T; Garner B; Cheng D
Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):142-160. PubMed ID: 27471947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
